InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: mojojojo post# 218841

Friday, 07/03/2015 9:34:13 PM

Friday, July 03, 2015 9:34:13 PM

Post# of 346409

I wonder if the recent departure of Mary Boyd was a result of having a deal in place?



looks like Mary Boyd finally decided to update her linkedin profile.

-------

Experience

Senior Advisor
InterPharmaLink AG
May 2007 – Present (8 years 3 months)Basel Area, Switzerland

InterPharmaLink AG (IPL) is a transaction oriented consultant to the healthcare industry specialised in partnering and M&A. The main activity of Senior Advisor is the identification and acquisition of business opportunities with special focus but not limited to Asia/Japan for IPL's business ( licensing, business development, corporate M&A, strategy consulting for pharmaceutical companies).


Head, Business Development, Asia & Europe
Peregrine Pharmaceuticals
August 2007 – February 2015 (7 years 7 months)

Peregrine is a NASDAQ listed bio-pharmaceutical company developing targeted monoclonal antibodies in the field of oncology. It has a fully owned subsidiary, Avid Bioservices, CMO, which is also located in Tustin, CA. My main duties were to manage business development activities with focus on Europe and Asia, from a base in Switzerland.

https://ch.linkedin.com/pub/mary-boyd/2/4/784

----------------------


.. I dont see her client Peregrine in this list of clients--- but since she takes the time to leave Peregrine on her profile, maybe you are correct and a deal is already completed...

http://www.interpharmalink.com/people.html

Abbott
Actera Group
Advent International
aenova
Amerisource Bergen
Ariad
Aspen Holdings
AstraZeneca
Bayer
Biofrontera
Biotest
Cambrex
Domain Associates
Dr. Reddy\'s
Famar Health Care Services
Ferring Pharmaceuticals
Fresenius Kabi
Grenzach Produktions GmbH
Galenica
Hermes Arzneimittel GmbH
Hikal
Kidd & Company
Kohlberg Kravis Roberts
Kyowa Kirin
Lonza
Madison Dearborn Partners
Millennium
Mitsubishi Tanabe Pharma
New Rhein Health Care
Nova Cardia
Ocera
Omrix
Otsuka
Patheon
Polpharma
Renaissance Pharma
Sato Healtcare Innovation
Siegfried
Stada Arzneimittel
Syndax
The Medicines Company
Tillots Pharma
Warburg Pincus
Weleda

http://www.interpharmalink.com/clients.html

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News